In a fresh public health development, officials have confirmed two new cases of measles in Cook County—one in the city of Chicago and another in the suburbs. These are the first reported cases of measles in the county for 2025, raising immediate concerns among health authorities and the general public alike.

According to a joint statement released by the Chicago Department of Public Health and the Cook County Department of Public Health, the two individuals diagnosed had visited multiple public places between April 21 and April 28, potentially exposing others to the virus during that time.

Where Were People Possibly Exposed?

Health officials have listed several high-traffic locations where others may have come into contact with the virus:

• April 21 – Fittingly Delicious, 3939 W. Irving Park Road
• April 22 & 23 (10 a.m. – 8 p.m.) – O’Hare Airport, Terminal 1
• April 25 (10 a.m. – 12:30 p.m.) – Aldi, 7235 39th St., Lyons
• April 27 (10 a.m. – 12:30 p.m.) – Shell, 3901 S. Harlem Ave., Stickney
• April 28 (10:20 a.m. – 1 p.m.) – Mobil, 2945 S. Harlem Ave., Berwyn

Initially, officials believed there may have been an exposure at the Chicago Public Library’s Independence Branch on April 21, but further investigation revealed that the infected individual did not visit that location. Therefore, no further action is needed for those who were at the library that day.

Semaglutide Shows Major Promise in Treating Serious Liver Disease, Landmark Study Reveals

Details About the Cases

The first case involves a Chicago adult who had traveled internationally through O’Hare International Airport in early April. The person developed a measles-related rash on April 25 and has since been isolating at home. They had received only one dose of the MMR (measles-mumps-rubella) vaccine, which provides partial protection.

The second case was found in a suburban Cook County resident, whose vaccination status remains unknown. This individual sought medical care on April 28 and was immediately isolated once measles symptoms were identified.

Health Department Response

Dr. Olusimbo Ige, Chicago’s Health Commissioner, emphasized that the city had successfully contained a measles outbreak in 2024, and they are confident in their ability to manage this situation as well.

“Chicago is no stranger to measles after our outbreak last spring, and having contained it once, we know we can do it again,” said Dr. Ige. “It’s never too late to get vaccinated and protect yourself from measles.”

The 2024 outbreak had primarily affected individuals in migrant shelters. Since then, public health authorities have intensified surveillance and vaccination efforts.

Measles: Why It’s Dangerous

Though measles is now rare in cities like Chicago—thanks largely to high vaccination coverage—it remains a highly contagious and serious illness, especially for those who are unvaccinated or under-vaccinated.

The virus spreads easily through the air and can linger in a room for up to two hours after an infected person has left. Symptoms generally develop 7 to 21 days after exposure and include:

• High fever
• Cough and runny nose
• Red, watery eyes
• Rash

Severe complications can arise, such as pneumonia, seizures, hearing loss, brain damage, and in rare cases, even death.

The Role of Vaccination

According to Dr. Sameer Vohra, Director of the Illinois Department of Public Health, the MMR vaccine remains the most effective defense against measles. It is widely available and recommended for everyone aged 1 year and above.

“The MMR vaccine is safe and effective,” Dr. Vohra said. “We encourage anyone who is unvaccinated, or under-vaccinated, to speak with their medical provider and take appropriate steps to get up to date on the recommended shots.”

A complete MMR vaccination typically involves two doses. One dose offers about 93% protection, while two doses increase that to 97%.

Combating Misinformation and Protecting the Community

Health officials warn that misinformation about vaccines has led to a decline in immunization rates, which could lead to more frequent outbreaks in the future.

Dr. Kiran Joshi, interim COO of the Cook County Health Department, strongly reaffirmed public confidence in the vaccine:

“The MMR vaccine has been in use for over 50 years. It’s highly effective and has protected millions of lives.”

What to Do If You Suspect Symptoms

Anyone who thinks they may have been exposed or is showing symptoms is urged not to visit a clinic or hospital without calling ahead. This will allow medical staff to take precautions and prevent potential spread to other patients.

Thanks for visiting Best Breaking News

In a significant medical breakthrough, researchers have found that semaglutide, a drug widely known for managing diabetes and aiding weight loss, may also be an effective treatment for a serious liver condition known as Metabolic Dysfunction-Associated Steatohepatitis (MASH). This finding comes from an extensive phase 3 clinical trial that involved 800 participants across 37 countries.

Semaglutide is the active compound in popular medications like Ozempic and Wegovy, which are primarily prescribed to help control blood sugar and reduce weight. But this new study shows it could go much further—offering hope to people suffering from advanced fatty liver disease.

What the Study Revealed

The clinical trial ran for 72 weeks and involved administering a weekly dose of semaglutide to one group, while another group received a placebo. The results are striking:

62.9% of the participants who received semaglutide showed significant improvements in MASH.

In comparison, only 34.3% of those on the placebo saw similar benefits.

The drug also reduced liver fibrosis (a form of scarring due to long-term liver damage) in 36.8% of treated patients, versus 22.4% in the placebo group.

Notably, 32.7% of patients experienced improvement in both MASH and fibrosis with semaglutide, compared to 16.1% in the control group.

These results are being seen as a major win for semaglutide, positioning it as a potential dual-action drug that not only addresses metabolic disorders like obesity and diabetes but also targets liver conditions.

Google Expands AI Mode Access – New Features Now Available to More Users in the U.S.

Expert Views on the Findings

Dr. Arun Sanyal, a leading liver disease specialist and professor of medicine at Virginia Commonwealth University, emphasized the significance of the findings.

“These results provide strong evidence that semaglutide can help patients with MASH—not just by improving liver health, but also by tackling the underlying metabolic issues that fuel the disease,” said Dr. Sanyal.

He also pointed out that the potential approval of semaglutide for MASH treatment could offer a much-needed option for patients, especially considering the links between MASH and other serious health conditions like heart disease, diabetes, and kidney disorders.

Why Semaglutide Works

Semaglutide works as a GLP-1 receptor agonist, which means it mimics the natural GLP-1 hormone in the body. This hormone plays a key role in managing appetite, insulin release, and blood sugar levels. Because MASH is closely tied to metabolic dysfunction, semaglutide’s ability to regulate these processes is likely what makes it effective in treating the liver condition.

Moreover, the drug is believed to reduce inflammation in the body, another crucial factor in slowing or reversing liver damage in MASH patients.

The Road Ahead

Although the initial results are promising, the researchers are not stopping here. The trial is continuing and will expand to a larger population over a five-year period to determine whether the improvements can be sustained long term.

Currently, there’s only one approved treatment available for MASH. Given how widespread and dangerous this disease is—especially among people with obesity and type 2 diabetes—new treatment options are urgently needed.

What This Means for Patients

If semaglutide is approved for MASH, it could change the treatment landscape for millions. It represents a holistic approach to chronic illness—targeting both liver disease and its underlying metabolic causes.

“By addressing both liver damage and the metabolic dysfunctions that contribute to it, semaglutide offers a new and promising strategy,” Dr. Sanyal said.

The study has been published in the New England Journal of Medicine, one of the world’s most respected medical journals, further underlining the importance of this discovery.

Thanks for visiting Best Breaking News